Sahil Koppikar, Bindee Kuriya, Jacob A Udell, Bing Yu, Anna Chu, Douglas S Lee, Jessica Widdifield, Lihi Eder
{"title":"免疫介导的炎症性疾病患者心力衰竭的风险：一项基于人群的研究","authors":"Sahil Koppikar, Bindee Kuriya, Jacob A Udell, Bing Yu, Anna Chu, Douglas S Lee, Jessica Widdifield, Lihi Eder","doi":"10.3899/jrheum.2024-0866","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the risk of heart failure (HF) in patients with immune-mediated inflammatory diseases (IMIDs) compared to the general population with and without diabetes mellitus (DM).</p><p><strong>Methods: </strong>A population-based cohort study was conducted in patients with rheumatoid arthritis (RA), radiographic axial spondyloarthritis (r-axSpA), psoriatic arthritis, and psoriasis (PsO) in Ontario from 2011 until 2019. The study outcome was first hospitalization for HF. Incidence rates of HF were calculated for each cohort. Hazard ratios (HRs) for HF were calculated using Cox proportional hazard models. The etiology of HF was descriptively classified into mutually exclusive groups based on comorbidities during HF hospitalization.</p><p><strong>Results: </strong>A total of 243,061 patients with IMID, 748,517 with DM, and 8,278,934 non-IMID, non-DM controls were analyzed. The crude incidence rate for HF in IMID was 2.70 per 1000 person-years, with the highest rate in RA and lowest in r-axSpA. The risk of being hospitalized for HF was higher in IMID compared with non-IMID comparators (HR 1.34, 95% CI 1.30-1.38). This risk was highest among patients with RA (HR 1.61, 95% CI 1.54-1.68) and lowest in PsO (HR 1.09, 95% CI 1.03-1.15). In comparison, the risk of HF hospitalization in patients with DM was higher (HR 2.19, 95% CI 2.16-2.21). The most common antecedent comorbidity associated with HF in all patients with IMID was ischemic heart disease. In patients with IMID without DM, atrial fibrillation had a similar effect as ischemic heart disease.</p><p><strong>Conclusion: </strong>The risk of HF hospitalization is increased in patients with IMID compared to the general population.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study.\",\"authors\":\"Sahil Koppikar, Bindee Kuriya, Jacob A Udell, Bing Yu, Anna Chu, Douglas S Lee, Jessica Widdifield, Lihi Eder\",\"doi\":\"10.3899/jrheum.2024-0866\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the risk of heart failure (HF) in patients with immune-mediated inflammatory diseases (IMIDs) compared to the general population with and without diabetes mellitus (DM).</p><p><strong>Methods: </strong>A population-based cohort study was conducted in patients with rheumatoid arthritis (RA), radiographic axial spondyloarthritis (r-axSpA), psoriatic arthritis, and psoriasis (PsO) in Ontario from 2011 until 2019. The study outcome was first hospitalization for HF. Incidence rates of HF were calculated for each cohort. Hazard ratios (HRs) for HF were calculated using Cox proportional hazard models. The etiology of HF was descriptively classified into mutually exclusive groups based on comorbidities during HF hospitalization.</p><p><strong>Results: </strong>A total of 243,061 patients with IMID, 748,517 with DM, and 8,278,934 non-IMID, non-DM controls were analyzed. The crude incidence rate for HF in IMID was 2.70 per 1000 person-years, with the highest rate in RA and lowest in r-axSpA. The risk of being hospitalized for HF was higher in IMID compared with non-IMID comparators (HR 1.34, 95% CI 1.30-1.38). This risk was highest among patients with RA (HR 1.61, 95% CI 1.54-1.68) and lowest in PsO (HR 1.09, 95% CI 1.03-1.15). In comparison, the risk of HF hospitalization in patients with DM was higher (HR 2.19, 95% CI 2.16-2.21). The most common antecedent comorbidity associated with HF in all patients with IMID was ischemic heart disease. In patients with IMID without DM, atrial fibrillation had a similar effect as ischemic heart disease.</p><p><strong>Conclusion: </strong>The risk of HF hospitalization is increased in patients with IMID compared to the general population.</p>\",\"PeriodicalId\":50064,\"journal\":{\"name\":\"Journal of Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.2024-0866\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2024-0866","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：评价免疫介导性炎症性疾病（IMIDs）患者发生心力衰竭（HF）的风险，并与有或无糖尿病（DM）的普通人群进行比较。方法：从2011年到2019年，在安大略省的类风湿性关节炎（RA）、影像学轴向性脊柱炎（r-axSpA）、银屑病关节炎和牛皮癣（PsO）患者中进行了一项基于人群的队列研究。研究结果是首次因心衰住院。计算每个队列的心衰发生率。采用Cox比例风险模型计算HF的风险比（hr）。根据HF住院期间的合并症，将HF的病因描述性地分为相互排斥的组。结果：共分析了243,061例IMID患者，748,517例DM患者和8,278,934例非IMID和非DM对照组。IMID患者HF的粗发病率为2.70 / 1000人年，RA发病率最高，r-axSpA发病率最低。与非IMID比较组相比，IMID组因HF住院的风险更高（HR 1.34, 95% CI 1.30-1.38）。RA患者的风险最高（HR 1.61, 95% CI 1.54-1.68）， PsO患者的风险最低（HR 1.09, 95% CI 1.03-1.15）。相比之下，合并糖尿病患者发生HF住院的风险更高（HR 2.19, 95% CI 2.16-2.21）。在所有IMID患者中，与HF相关的最常见的既往合并症是缺血性心脏病。在没有糖尿病的IMID患者中，房颤的影响与缺血性心脏病相似。结论：与普通人群相比，IMID患者HF住院的风险增加。
Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study.
Objective: To evaluate the risk of heart failure (HF) in patients with immune-mediated inflammatory diseases (IMIDs) compared to the general population with and without diabetes mellitus (DM).
Methods: A population-based cohort study was conducted in patients with rheumatoid arthritis (RA), radiographic axial spondyloarthritis (r-axSpA), psoriatic arthritis, and psoriasis (PsO) in Ontario from 2011 until 2019. The study outcome was first hospitalization for HF. Incidence rates of HF were calculated for each cohort. Hazard ratios (HRs) for HF were calculated using Cox proportional hazard models. The etiology of HF was descriptively classified into mutually exclusive groups based on comorbidities during HF hospitalization.
Results: A total of 243,061 patients with IMID, 748,517 with DM, and 8,278,934 non-IMID, non-DM controls were analyzed. The crude incidence rate for HF in IMID was 2.70 per 1000 person-years, with the highest rate in RA and lowest in r-axSpA. The risk of being hospitalized for HF was higher in IMID compared with non-IMID comparators (HR 1.34, 95% CI 1.30-1.38). This risk was highest among patients with RA (HR 1.61, 95% CI 1.54-1.68) and lowest in PsO (HR 1.09, 95% CI 1.03-1.15). In comparison, the risk of HF hospitalization in patients with DM was higher (HR 2.19, 95% CI 2.16-2.21). The most common antecedent comorbidity associated with HF in all patients with IMID was ischemic heart disease. In patients with IMID without DM, atrial fibrillation had a similar effect as ischemic heart disease.
Conclusion: The risk of HF hospitalization is increased in patients with IMID compared to the general population.
期刊介绍：
The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
